Ptc Therapeutics (PTCT) Net Equity Issued and Repurchased (2012 - 2020)

Ptc Therapeutics' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $9.1 million for Q3 2020.

• On a quarterly basis, Net Equity Issued and Repurchased fell 90.83% year-over-year to $9.1 million in Q3 2020; TTM through Dec 2020 was $28.1 million, a 91.32% decrease from a year earlier, with the FY2020 full-year figure at $28.1 million, down 91.32% from the prior year.
• Net Equity Issued and Repurchased grew to $9.1 million in Q3 2020 per PTCT's latest filing, from $5.4 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $224.4 million in Q1 2019 and bottomed at -$506000.0 in Q4 2019.
• The 3-year median for Net Equity Issued and Repurchased is $2.8 million (2019), against an average of $35.2 million.
• Biggest YoY gain for Net Equity Issued and Repurchased was 243112.2% in 2019; the steepest drop was 50700.0% in 2019.
• Year by year, Net Equity Issued and Repurchased stood at $1000.0 in 2018, then sank by 50700.0% to -$506000.0 in 2019, then soared by 1906.72% to $9.1 million in 2020.
• Per Business Quant, the three latest PTCT Net Equity Issued and Repurchased figures stand at $9.1 million (Q3 2020), $5.4 million (Q2 2020), and $13.5 million (Q1 2020).